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Signiﬁcant evidence has now been accumulated that microglial cells play a central role in the degeneration of DA neurons
in animal models of PD. The oxidative stress response by microglial cells, most notably the activity of the enzyme NADPH
oxidase, appears to play a central role in the pathology of PD. This oxidative stress response occurs in microglia through the
activation of the ERK signaling pathway by proinﬂammatory stimuli, leading to the phosphorylation and translocation of the
p47phox and p67phox cytosolic subunits, the activation of membrane-bound PHOX, and the production of ROS. Therapeutic anti-
inﬂammatories which prevent DA neurodegeneration in PD, including anti-inﬂammatory cytokines, morphinan compounds,
NADPH oxidase inhibitors, NF-κB inhibitors, and β2-AR agonists, all function to inhibit the activation of the PHOX in microglial
cells. These observations suggest a central role for the oxidative stress response in microglial cells as a mediator or regulator of DA
neurodegeneration in PD.
1. Neurodegeneration and Inﬂammation in
Parkinson’sDisease
Parkinson’s disease (PD) is a progressive degenerative dis-
order of the central nervous system (CNS) that leads to
impairment of motor skills and speech, as well as other
functions [1]. In the United States, it is estimated that
between 0.1-0.2% of all individuals are at some stage in the
progression of Parkinson’s Disease. This rate is somewhat
higher in the elderly and those experiencing head trauma.
There are several diﬀerent forms of Parkinson’s disease, with
the most common being either the familial or the idiopathic
forms. The familial forms result from alterations in genes
such as α-synuclein, LRRK2, parkin, PINK-1, or DJ-1 [2–
7], while the idiopathic forms arise from environmental
factors such as exposure to toxins, head trauma, infection,
or unknown etiology [8–13]. While onset before age 30
is rare, up to 10% of cases of idiopathic PD begin by
age 50 [14]. The primary symptoms of PD are caused by
the insuﬃcient formation and action of dopamine, and
they are manifest by decreased stimulation of the motor
cortex by the basal ganglia. The loss of dopamine, which
is predominantly produced by the DA neurons within the
substantia nigra (SN) region and striatum of the brain,
results in tremors, muscle rigidity, cognitive dysfunction,
changes in speech patterns, muscle rigidity, and a dynamic
progressive dysfunction that can lead to a total loss of all
physical movement and ultimately death [7, 15–18].
Although the disease mechanisms that ultimately cause
PD are still not fully understood, it is believed that the
progressive nature of Parkinson’s disease is characterized
by chronic inﬂammation-induced neurodegeneration of
dopamine-producing neurons within the SN and striatum
[13, 19–23]. It is now well documented that microglial
activation results in the loss of dopaminergic neurons (DA-
neurons) in patients with PD [24–28]. Additionally, levels
of proinﬂammatory cytokines, including TNFα,I L - 1 β,I L -
6, as well as reactive oxygen species (ROS) are elevated in
the brains and peripheral blood mononuclear cells (PBMCs)
of patients with PD [29–31]. Nitrite in the cerebrospinal
ﬂuid as well as increased expression of inducible nitric oxide
synthase (iNOS) within the SN has also been found in PD
patients[32,33],contributingtostrongevidenceofoxidative
stress in the SN of PD patients [25, 34]. These observations,
taken together suggest that progressive PD is driven by the
inﬂammatoryresponseofmicroglialcells,andthattheaction2 Mediators of Inﬂammation
of these cells, including oxidative stress responses and ROS
production, may play a key role in the neurodegeneration
seen in PD.
2.MicroglialCellsandOxidativeStress in
Parkinson’sDisease
The etiology of idiopathic PD now suggests that chronic
production of inﬂammatory mediators by microglial cells,
[31, 32, 35], particularly the generation of ROS and NO by
activatedmicroglia[23,33,34,36,37],mediatesthemajority
of DA-neuronal tissue destruction [38]. Microglia are the
resident macrophages of the brain and as such play critical
roles in the development and maintenance of the neural
environment [39]. Although microglia continually survey
the surrounding tissue, they remain in essentially a quiescent
state under tight regulation until they become activated in
response to perturbations in the brain’s microenvironment
or changes in the neuronal structure. Resting microglia
continually “sense” conditions in the surrounding tissue by
extending and contracting their cellular processes, and their
encounter with extracellular triggers such as those from
pathogens, structurally or genetically altered proteins, and
dead or dying neuronal cells will activate a strong proinﬂam-
matory response [39, 40]. Once activated, microglia undergo
morphological changes as well as phenotypic alterations
in gene expression and production/activation of signaling
molecules. More importantly, microglia will mount a series
of responses, starting with the oxidative stress response, to
produce mediators which help to eliminate the source of
these proinﬂammatory signals. These activated microglia
have dichotomous roles in neuroinﬂammation in that they
can both mediate the inﬂammatory response by producing
mediators which function to clear the source of the inﬂam-
matory stimuli, and they can regulate the inﬂammatory
response by perpetuating the proinﬂammatory response
through the continued release of inﬂammatory products
which function to activate and regulate microglia and
astrocyte responses. Conversely, when the inﬂammatory
stimuli have been removed, microglia can function to
promote neurogenesis through the release of neurotrophins
and anti-inﬂammatory cytokines, potentially leading to
neuroregeneration and wound healing within the SN and
striatum [39, 41–44].
There are a number of pro-inﬂammatory stimuli by
which microglial cells can be activated to mediate DA-
neurotoxicity in rodent models of PD. Agents that directly
activate microglia have been shown to lead to the loss of DA-
producing neurons both in vitro and in vivo. These include
LPS [37, 45, 46] and nitrated-α-synuclein [47]. In addi-
tion, several direct neurotoxins, such as 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine(MPTP)and6-hydroxydopamine
(6-OHDA), can activate microglia through a process called
reactive microgliosis, which leads to exacerbation of DA-
neuron neurotoxicity [25, 28, 48–51] .T h e r ei sa l s oas t r o n g
correlation in human patients between proinﬂammatory
signals in the brain, including inﬂammation caused by
traumatic brain injury [52] and infection [53, 54], and
the ultimate onset of PD. Once activated, microglial cells
produce a wide variety of inﬂammatory mediators which
serve to mediate an innate immune response, including
ROS and the related NO. NF-κB and MAP-kinase signal-
ing pathways control gene expression of many of these
proinﬂammatory cytokines, chemokines, and enzymes that
produce these secondary inﬂammatory mediators [54–57].
Our recent work, and that of others using rodent models of
DA neurodegeneration, has shown that the oxidative stress
response plays a central role in the etiology of PD [58–
61] and that anti-inﬂammatory therapeutics that inhibit
the oxidative stress response in microglial cells can be
neuroprotective [59–61]. Furthermore, animal studies have
demonstrated that the generation of ROS is an upstream
event which regulates the production of other proinﬂamma-
tory factors such as TNFα and IL-1β through its regulation
of the transcription factor NF-κB[ 62, 63]. Furthermore, the
postmortem detection of elevated levels of ROS and NO, and
evidence of oxidative-stress-mediated damage in the brain of
PD patients, strongly implies microglial-induced ROS and
NO involvement in the chronic degenerative process in vivo.
Therefore, it appears that the oxidative stress response in
microglial cells may be an important component of both the
DA neurodegenerative response, and in the maintenance of
the chronic pro-inﬂammatory response seen in PD patients.
Further evidence for the central role of ROS in DA
neurodegeneration and PD is found in animal model
systems which exhibit hyperactive microglial cells. In the
normal, healthy brain, microglia are in intimate contact
with neurons which maintain the microglia in the quiescent
state by means of membrane-bound and secreted signaling
molecules [64–66]. The most important of these suppression
signals appears to be CD200 expressed on neurons and
endothelial cells within the CNS and its interaction with
the receptor CD200R, which is expressed on the microglia
[64, 67, 68]. Interaction of CD200 and the receptor, between
contacting neurons and microglia, helps to maintain the
microglia in the inactive state [64, 67–71], since mice lacking
expression of CD200 exhibit microglia with morphology
typical of activated cells as well as heightened expression of
activation markers CD11b and CD45 [69]. Microglial cells
from CD200 deﬁcient mice also release elevated levels of
inﬂammatory mediators TNFα, ROS, and NO subsequent
to an immune challenge [69] .Ar a tm o d e lo fP Du s i n g
mixedculturesofmesencephalicneuronsandmicroglialcells
showed that treatment with a function neutralizing antibody
to CD200R enhances the susceptibility of DA neurons to
neurotoxic insult [71]. Similar results were found when the
mixed cultures were subjected to insult by the addition of
iron in another cellular model of PD [71]. Signiﬁcantly,
the neutralizing antibody-treated cultures showed increased
levels of NADPH oxidase-mediated superoxide production
which was found to be the critical factor in DA-neuron
neurotoxicity. Treatment with the superoxide inhibitors,
superoxide dismutase (SOD) or catalase, attenuated the loss
of DA neurons in mixed cultures treated with the anti-
CD200R antibodies plus neurotoxins. Similarly, the NADPH
oxidase inhibitor, apocynin, also blocked the antibody-
toxin eﬀects on DA neuron survival [71]. ImpairmentMediators of Inﬂammation 3
of CD200-CD200R interaction is functionally associated
with microglial activation and the increased death of DA
neurons which is induced by enhanced NADPH oxidase-
mediatedsuperoxideproductionasthekillingfactor[69,71].
Changes in the microenvironment at the cell surface of the
microglia are thus ampliﬁed into intracellular signals that
result in release of ROS which then can act as both direct
eﬀectors in neurotoxicity, and as secondary signaling factors
that participate in stimulation of the production of other
neuroinﬂammatory mediators.
NADPH oxidase (PHOX) is the major enzyme for the
production of extracellular superoxide in immune cells and
is highly expressed in microglia. It has been found that
the activation of microglia by pro-inﬂammatory stimuli
such as lipopolysaccharide (LPS) can lead to activation
of PHOX through an ERK-dependent mechanism via the
phosphorylation and translocation of cytosolic components
of PHOX, including the p47phox and p67phox cytosolic
subunitsofPHOX[61].Wehavefoundthatphosphorylation
of Ser345on p47phox is a prerequisite to the degeneration of
DA neurons both in vivo and in vitro, and that signiﬁcantly
decreased DA neurotoxicity is seen in both PHOX−/− mice
(in vivo)a n dP H O X −/− midbrain neuron/glia cultures (in
vitro) than in PHOX+/+ controls [72]. Furthermore, DPI
(diphenylene iodonium), a widely used NADPH oxidase
inhibitor, has been found to have signiﬁcant therapeutic
eﬀects in a number of inﬂammatory diseases, including liver
disease, exothermia, and EAE [73–76], and now appears
to have eﬃcacy as a therapeutic to prevent DA neurode-
generation in PD (see below). These observations suggest
that the oxidative stress response, more speciﬁcally the one
mediated by NADPH oxidase, may have a central role in DA
neurodegeneration.
3. ROS and Neuroinﬂammation
Reactive oxygen species (ROS) include molecules such
as superoxide (O2
−) and hydrogen peroxide (H2O2). In
addition, H2O2 is associated with the generation of nitric
oxide (NO), another reactive species. While ROS have some
essential roles in normal cell functions [77], they are more
associated with their pathological eﬀects that ultimately lead
to protein and cellular damage as well as cell death [78–81].
Extracellular insults, which include inﬂammation, stimulate
production of ROS to hyperphysiological concentrations
that results in oxidative stress. Under oxidative stress,
redox reactions modulate proteins and generate changes
in intracellular and intercellular signaling pathways that
drive changes in cellular responses [71]. Diﬀerent levels of
oxidative stress induce disparate consequences for cellular
function including proliferation, diﬀerentiation, and cell
death. At high levels of ROS production, proteins become
inactivated or damaged resulting in cellular degeneration
and death. In this context, redox-sensitive proteins transduce
redox changes into signals that induce cellular responses.
Thus, proteins can be viewed as “redox sensors” that can
aﬀect modiﬁcations in their own localization, abundance,
and activities [71]. Redox-modiﬁed proteins can also aﬀect
changes (conformational, posttranslational, etc.) in other
proteins as is the nature of signaling pathways [71, 82]. At
nonlethal levels, the redox state of the proteins and cells can
be reversible and the molecular basis of the redox changes
occurs mainly on the cysteine residues. Signaling events, ini-
tiatedbythiol-basedredoxchangesonthecysteines,emanate
from the protein and are transmitted to other molecules
in the signaling pathway via conformational changes, post-
translational modiﬁcations, and translocations. In this way,
thethiol-cysteineshavebeencalled“molecularswitches”and
these actions have been elucidated for various components
of signaling pathways including proteases, kinases, and
transcription factors [71].
Among the transcription factors that are responsive to
redox-based signaling in microglial cells is NF-κB[ 83]. NF-
κB consists of two subunits which can vary according to
the signaling pathway that is activated by cellular events
[54, 55] (see Figure 1). Rel A (p65) and p50 are the subunits
that form the heterodimer in the canonical NF-κBp a t h w a y ,
and the p65/p50 dimer normally remains inactive in the
cell’s cytoplasm in complex with the IκB inhibitor protein
[54, 55]. When the pathway is induced by some stimuli such
as oxidative stress, IκBi sd e g r a d e da n dN F - κB is released to
translocate to the nucleus where it binds DNA to activate
transcription of genes [54, 55, 84]. It has been shown that
the presence of ROS can induce activation of NF-κBi n
the cytoplasm but can conversely inhibit NF-κBa c t i v i t y
in the nucleus [83]. Oxidation of p50 within the DNA-
binding domain inhibits DNA binding thus mediating direct
ROS regulation of NF-κB transcriptional activity. ROS can
also indirectly control NF-κB-DNA binding by regulating
serine phosphorylation of p65 which is necessary for RelA-
DNA interaction [85]. However, ROS could both inhibit
and promote NF-κB activity in what has been suggested
as a biphasic redox-sensitive response [86–89]. When only
slight increases in ROS levels are induced in the cytoplasm,
then small increases in IκB degradation occur. Excessive
ROS, especially when present in the nucleus, results in
oxidation-mediated inhibition of NF-κB-DNA binding [89].
This suggests that moderate increases in ROS induce IκB
degradation, leading to transcriptional activation which is
usually prosurvival. Conversely, when ROS becomes exces-
siveinthemicroenvironment,thenucleusbecomesoxidative
which inhibits NF-κB transcriptional activity and abolishes
prosurvival gene expression [89]. What this means for ROS
and NF-κB-mediated neurodegeneration is not clear since
inhibition of NF-κB activity or blocking ROS production has
been shown to promote neuronal survival in both cellular
and animal models of PD [27, 90]. Since activated microglia
areapartoftheclearancephaseofaninﬂammatoryresponse
and are additionally an important source of neurotrophins
in neurogeneration, microglial survival at moderate levels of
ROS is crucial to their physiological function. Signiﬁcantly,
these cysteine-thiol-based oxidative responses to ROS are
reversible suggesting signaling mechanisms similar to phos-
phorylation and dephosphorylation of molecular switches
[89]. As with the case of phosphorylation-based signaling,
ROS signaling could have stimuli-speciﬁc and cell-type-
speciﬁc mechanisms.4 Mediators of Inﬂammation
TNFR1
MEKK3
IKKβ activation
LPS TNFα
CD14/
TLR4
p50 p65
p50 p65
IKKα IKKβ
p100 phosphorylation
Nucleus
CD40
NIK
BAFF CD40L
BAFFR
IKKα IKKα
RelB p100
RelB p100
Canonical
IKKγ
IKKα activation
Target—inﬂammatory genes Target—growth and survival genes
IκB-α
IκBα phosphorylation
Signaling pathways of NF-κB
Noncanonical
Figure 1: Canonical and noncanonical pathways of NF-κB activation. Proinﬂammatory activation signals such as LPS or TNFα activate the
canonical pathway through the activation of the IKK complex, which includes the subunits IKKγ (NF-κB essential modulator, or NEMO),
IKKα, and IKKβ. This complex then phosphorylates IkBα (the NF-κB inhibitor), which causes it to be ubiquitinated and proteolytically
cleaved by the proteosome, releasing the p50/p65 heterodimer to be translocated to the nucleus, where it transcriptionally activates
proinﬂammatory genes, including p47 and p67 of the NADPH oxidase complex. Growth and diﬀerentiation signals such as BAFF and
CD40L activate the noncanonical pathway, which is initiated by NF-κB inducing kinase (NIK), which phosphorylates the IKKα homidimer
complex which does not require either IKKγ or IKKβ, which subsequently phosphorylates the p100 subunit of the p100/RelB complex. The
p100 protein is cleaved, which allows the p52/RelB complex to translocate to the nucleus and activate a number of growth and survival genes
in target cells.
In phagocytes such as microglia, ROS production can
be generated from several sources including intracellu-
lar peroxidases, oxidative processes in mitochondria, and
NADPH oxidase activity at the cell-surface membrane [24].
Under physiological conditions, superoxide, hydroxyl radi-
cal, and hydrogen peroxide are normal byproducts of oxygen
metabolism by mitochondria [77, 89]. Superoxide is gener-
ated from mitochondrial complexes I and III of the electron
transport chain and can be reduced to H2O2 which is also
produced by peroxisomes [89, 91]. Normally, the catalase
in peroxisomes decomposes H2O2 thus preventing its toxic
accumulation in the cell. Under pathological conditions,
catalase activity is downregulated, H2O2 is released into
the cytosol increasing oxidative stress and, in the presence
of reduced metals, is converted to the hydroxyl radical.
Superoxide can also react with nitric oxide to produce
peroxynitrite (PN) which is an extremely active oxidizing
agent [91, 92]. Excess production of reactive oxygen and
nitrogen species in PD is thought to damage lipids, proteins,
and DNA as shown postmortem by high levels of lipid
peroxidation products, oxidized and damaged proteins, as
well as oxidized DNA in the CNS of PD patients [18, 93].
PN-modiﬁed proteins have been found to accumulate in
the Lewy bodies of the cells in PD brains and PN has been
shown to inhibit complex-I-mediated cellular respiration
[82, 91, 92, 94–96].
4. Successful Therapies to
DA Neurodegeneration Also Target
the OxidativeStress Response
Emerging evidence demonstrates that numerous inﬂamma-
tory mediators such as ROS free radicals, NO, and other
products of activated immune cells can play a role in
the degeneration of SN dopamine-producing neurons in
several rodent models of PD [36, 79]. Therefore, it is likely
that treatment with anti-inﬂammatory reagents directed at
these proinﬂammatory targets could also potentially halt or
slow DA neurodegeneration in these rodent models. ForMediators of Inﬂammation 5
example, steroidal anti-inﬂammatory drugs (SAIDs) such as
dexamethasone have been reported to show neuroprotection
against MPTP- or LPS-induced toxicity in rodents [97, 98].
Nonsteroidal anti-inﬂammatory drugs (NSAIDS) such as
aspirin and ibuprofen reduce inﬂammation by inhibition of
COX activity and have been found to be modestly eﬀective
at slowing the progression of neurodegeneration in the
MPTP rodent model [99]. Recently, strategies that block the
canonical form of the proinﬂammatory transcription factor
NF-κB[ 27, 100], and activating the peroxisome proliferator-
activated receptor-γ (PPARγ)[ 101, 102], have shown bene-
ﬁcial eﬀects in the modulation of inﬂammatory responses in
mice and rats. We have used ﬁve relatively novel approaches
in anti-inﬂammatory therapy to prevent DA neurodegener-
ation in rodent models of PD, and these approaches include
(1) the use of endogenous anti-inﬂammatory cytokines IL10
or TGFβ1, (2) the use of morphinan-related compounds; (3)
the use of PHOX inhibitor DPI; (4) the targeting of IKK,
a major component of the signaling pathway activating the
canonical form of NF-κB, which is the major transcriptional
regulator of inﬂammation; (5) the use of β-2 adrenergic
receptor (β-2AR) agonists. While none of these studies have
yetbeenusedonhumanpatients,wewillreviewtheevidence
suggesting that these successful therapies in rodents target
the oxidative stress response in microglia. Furthermore, the
eﬀect of L-DOPA therapy on microglial-mediated oxidative
stress responses in rodent models of DA neurodegeneration
and in patients with PD will be reviewed.
5. Therapies Using Anti-Inﬂammatory
CytokinesIL-10 andTGFβ1
When ROS is the product of activated microglial cells
found in the proinﬂammatory state, endogenous anti-
inﬂammatory cytokines are also produced by microglial
cells following elimination of the proinﬂammatory signal to
provide a negative-feedback mechanism which converts the
microglia to a wound-healing phenotype. [103, 104]. IL10
and TGFβ1 are two major anti-inﬂammatory cytokines that
regulate the inﬂammatory response by inhibiting the pro-
duction of proinﬂammatory mediators by microglia. Studies
using exogenously supplied IL10 and TGFβ1 have shown
potenteﬀectsatinhibitingthecanonicalsignalingpathwayof
NF-κB and in reducing neurotoxicity induced by either LPS
or MPTP in PD models [60, 104–106]. We have found using
an in vitro model of PD that the addition of IL-10 to a mixed
glial cell-neuron cell culture abrogated the degeneration of
the neuron cells induced by either LPS or MPTP [60], and
this inhibitory eﬀect was mediated through its inhibition of
the production of extracellular superoxide in the microglia
cellswithin the mixed cellculture[105]. Thesein vitro eﬀects
of IL-10 are conﬁrmed by in vivo results from a 6-OHDA
rat model of PD. In this model, sustained administration
of IL10 via a viral vector signiﬁcantly protected DA-neuron
from death and ameliorated behavioral deﬁcits induced by
intrastriatal delivery of 6-OHDA [106]. Likewise, in vitro
or in vivo studies have shown that TGFβ1 can also protect
neurons from cell death induced by oxidative stress [107]
We have strong evidence that the neuroprotective eﬀects of
both IL-10 and TGFβ1 are mainly due to their inhibition
of NF-κB and ROS production in microglia during initial
activation or in reactive microgliosis [60, 108]. TGFβ1 also
prevents the ERK-dependent phosphorylation on p47phox in
the microglial cells and blocked translocation and assembly
of the PHOX molecular complex to the plasma membrane.
InhibitionofPHOXactivationconsequentlyreducedoxidase
activities induced by LPS [108]. While the complete in
vivo roles of IL10 and TGFβ1 in the prevention of DA
neurodegeneration in PD remain to be determined, both
appear to function, at least in part, by the inhibition of
oxidative stress responses in microglia.
6.Morphinan-BasedAnti-Inﬂammatory
Therapeutics
Several studies using PD animal models or in vitro cell
cultures have shown that the morphinan compound dex-
tromethorphan (DM) and its metabolites are neuroprotec-
tive due totheir anti-inﬂammatory properties andinhibitory
function towards microglia activation [59, 109, 110]. DM
inhibits microglia activation and is neuroprotective when
administereddailytomicethathadbeeninjectedwithMPTP
[109]. Another metabolite of DM, 3-hydroxymorphinan (3-
HM) was shown to have the greatest potency (of several
tested methorphanins) for attenuating the loss of DA
neurons in the SN, as well as restoring motor functions
in the same MPTP-mouse model of PD [110], and clini-
cal trials using 3-HM are currently underway in patients
with progressive PD. The use of 3-HM in vitro protected
neuronal cells in mixed glial-neuronal cells cultures by
reducing MPTP-induced microgliosis and decreasing the
production of ROS. [111]. Likewise, the use of other mor-
phinan compounds, including sinomenine, a morphinan-
related alkaloid compound puriﬁed from a medicinal plant
(Sinomenineacutum)thathasbeentraditionallyusedtotreat
inﬂammatory disorders [112, 113], and d-morphine, the
dextrorotatory form of the narcotic l-morphine, both show
strong neuroprotective eﬀects when used both in vitro and
in vivo. In all cases with these morphinan compounds, the
major eﬀect of these compounds was to inhibit microglial
inﬂammatory responses through the inhibition of both
NF-κB activation and subsequently ERK phosphorylation,
preventing the p47phox from translocating to the plasma
membrane where the complex becomes activated, and
resulting in the reduction of the release of extracellular ROS
[108].
7.Therapies usingNADPH Inhibitors
Diphenyliodonium (DPI), a NADPH oxidase inhibitor,
shows potent anti-inﬂammatory and neuroprotective eﬀects
in primary midbrain cultures, and in the LPS rodent model
of PD in vivo [73]. Mechanistic studies revealed that DPI-
elicited eﬀects were mediated by the inhibition of LPS-
induced microglial ROS production and the subsequent6 Mediators of Inﬂammation
releaseofpro-inﬂammatorycytokineTNFα,andtheproduc-
tion of nitric oxide. Further studies showed that DPI signif-
icantly reduced LPS-induced ERK phosphorylation, and the
subsequentphosphorylationandtranslocationofthep47phox
cytosolic subunit [73, 108]. Taken together, our results
demonstrate that DPI exerts potent anti-inﬂammatory and
neuroprotective eﬀects by inhibiting microglial activation
through the inhibition of ERK-regulated PHOX activity.
8. Therapies Targeting IKK/NF-κB
Given the importance of the canonical form of transcription
factor NF-κB in both the production of the components
of the oxidative stress response (p47 and p67 are regu-
lated by NF-κB), and in the regulatory eﬀects of ROS in
activating microglia (NF-κB controls ERK activity induced
by LPS signaling, Figure 2), inhibitors of the canonical
pathway of NF-κB should provide strong evidence of the
role of oxidative stress responses in PD. Therefore, a key
strategy for inhibiting neuroinﬂammation is to target the
canonical pathway of NF-κB activation without inhibiting
the noncanonical pathway, which is mainly involved in cell
growth, diﬀerentiation, and cell survival. In fact, speciﬁc NF-
κB inhibitors have recently been demonstrated to halt the
progressionofneurodegenerationinducedbytheneurotoxin
MPTP in murine models of PD [27], or by activation of
CNS inﬂammation by the intracranial injection of LPS [90].
The approach was to inhibit the canonical signaling pathway
of NF-κB without inhibiting the noncanonical pathway of
activation by targeting the unique kinase complex of the
canonical pathway called IKK (for the diﬀerence between the
canonicalandnoncanonicalsignalingpathway,seeFigure 1).
UtilizingapeptideagainstIKKγ,whichisdirectedagainstthe
NEMO-binding domain (NBD peptide) prior to injection of
MPTP into mice signiﬁcantly, inhibits the activation of NF-
κB within the midbrain region [27]. This inhibition of NF-
κB activation is accompanied by a concomitant reduction
in NADPH activity and ROS production, as well as the
expression of microglial cell activation marker CD11b. This
protection was also seen if administration of NBD peptide
was done 2 days after injection of MPTP, suggesting that
NBD peptide can be used therapeutically to slow down or
halt the progression of DA neurodegeneration in MPTP-
treated animals [27].
Likewise, use of a small molecule inhibitor of IKKβ,
called Compound A, had identical results in inhibiting ROS
production from microglial cells in vitro, and in protecting
DA neurons from LPS-induced neurodegeneration in vitro
and in vivo [90]. While the speciﬁc inﬂammatory media-
tor(s) targeted by of NF-κB inhibition within microglial cells
remains to be determined, these data suggest that inhibition
of ROS production using NF-κB inhibitors may be a key
component of the neuroprotection seen in PD patients [27].
9. Therapies Utilizing β2-ARAgonists
A recent family of compounds that have shown the potential
to reduce inﬂammation and DA neurodegeneration in
animal models are the long-acting β2-adrenergic receptor
(β2-AR) agonists [114–120]. These β2-AR agonists exist
in both short-acting and long-acting forms, and pharma-
cological studies have indicated that long-acting agonists
are quite eﬀective at inhibiting the inﬂammatory responses
of macrophage and microglial cells. We have found that
many of these long-acting agonists, including salmeterol
(found in Advair) and formoterol (found in Symbicort)
can inhibit the microglial oxidative stress response and
inﬂammatory mediator production, as well as inhibiting DA
neurodegeneration in vitro [121]. Furthermore, therapeutic
administration of the long-acting β2-AR agonist salmeterol
signiﬁcantly protects DA neurons against LPS- and MPTP-
induced cytotoxicity in vivo [121]. It is important to note
that the dosages used to treat progressive neurodegeneration
induced by either LPS or MPTP in mice are far below
those currently used to treat patients with COPD, the
current indication for this class of compounds (121), and
we have previously found that exposure of macrophages and
microglial cells to high or chronic doses of salmeterol can
actually exacerbate rather than inhibit the inﬂammatory and
oxidativestressresponseinthesecells[122].Ourmechanistic
studies indicate that the low-dose anti-inﬂammatory eﬀects
of salmeterol are mediated through the inhibition of both
MAPKandNF–κBsignalingpathwaysinactivatedmicroglia,
function independently of the canonical GPCR/cAMP/PKA
signaling pathway, and mediate their eﬀects only in PHOX+
cells. Therefore, it appears that these agonists function at
least in part through the inhibition of ROS production by
NADPH oxidase and add additional evidence of the central
role of the oxidative stress response in microglia as a key
component of DA neurodegeneration in PD. Furthermore,
although no clinical or epidemiological data yet exists to
suggest that the use of β2-AR agonists has any beneﬁcial
eﬀectonslowingorstoppingtheprogressionofPDinhuman
patients, our data suggests that this class of therapeutics,
particularly salmeterol, may be a new and highly eﬀective
treatment to halt the progression of not only PD but
also other neuroinﬂammatory diseases. However, given the
potential for both pro- and anti-inﬂammatory reactions on
microglial cells, therapeutic regimens using β2-AR agonists
in the treatment of PD will need to be carefully developed
and studied to determine the ultimate eﬃcacy of these
compounds.
10. Therapy Utilizing L-DOPA
Currently, it is believed that the progression of PD is also
due to oxidative stress damage not only from microglia, but
also from within the neurons themselves due in large part
to increased dopamine turnover, [123, 124]. The current
standardofcareforthetreatmentofPDistheadministration
of L-3,4-dihydroxyphenylalanine (L-DOPA), which in the
short term relieves many of the symptoms of PD but has
also been found to induce an oxidative stress response
in DA-neurons [125–127]. It is believed that L-DOPA at
high doses actually leads to cell death in neurons due to
its activation of apoptosis through the ASK1 and MAP-KMediators of Inﬂammation 7
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Figure 2: Chronic production of inﬂammatory mediators by microglial cells, particularly the generation of ROS and NO by activated
microglia, mediates the majority of DA-neuronal degeneration and cell death. As resident brain macrophages, microglia continually survey
the surrounding tissue where they remain in an inactive, quiescent state under tight regulation such as by the interaction of cell-surface
molecules CD200 (expressed on neurons) and CD200R receptor on the microglia. Microglia become activated when they encounter
extracellular triggers such as those from the pathogens, structurally or genetically altered proteins, toxins, and dead or dying neuronal
cells. Activated microglia generate a strong proinﬂammatory response including the production of inﬂammatory cytokines (e.g., TNFα,
IL-6, IL-1β) and an oxidative stress response. Most notably, the activity of the oxidative-stress enzyme, NADPH oxidase, appears to play a
central role in the pathology of DA-neuron death and the progression of PD. This oxidative stress response occurs in microglia through the
activation of the ERK signaling pathway by proinﬂammatory stimuli, leading to the phosphorylation and translocation of the p47phox and
p67phox cytosolic subunits, the activation of membrane-bound PHOX, and the production of ROS. Therapeutic anti-inﬂammatories which
prevent DA neurodegeneration in PD models, including anti-inﬂammatory cytokines, morphinan compounds, NADPH oxidase inhibitors,
NF-κB inhibitors, and β2-AR agonists, all function to inhibit the activation of the PHOX complex and ROS production in microglial cells.
signaling pathways [127, 128]. Furthermore, higher levels of
markers for oxidative stress were found in patients with PD,
but the origin and response of these markers to L-DOPA
therapy appear to be controversial [129]. However, given the
central nature of microglial cells and neuroinﬂammation in
the pathogenesis of PD, it is important to determine the
role of L-DOPA therapy on the redox reaction of microglial
cells. It has been found that the oxidative stress of peripheral
blood mononuclear cells (PBMCS) from patients with PD
appears to be higher than healthy patients, but L-DOPA
therapy actually appears to lower the redox response of these
PBMCs [130]. Therefore, while L-DOPA-induced oxidative
stress may play an important role in the direct toxicity of
DA neurons seen in progressive PD, the eﬀect of L-DOPA
therapy on the oxidative stress response of macrophages and
microglial cells and its direct damage on DA neurons is
still not determined, and the anti-inﬂammatory eﬀects of L-
DOPA therapy may actually play a role in short-term therapy
to help to protect DA-neurons from inﬂammatory damage
mediated by activated microglial cells.
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